Finally, in the setting of HER2-positive metastatic disease, the fixed-dose subcutaneous formulation of pertuzumab/trastuzumab was also approved, based on the FeDeriCa trial results [39]. This evidence concerns the gene ERBB2 and metastatic neoplasm.